These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15921302)

  • 1. [Stem cell transplantation in the imatinib era].
    Masszi T
    Orv Hetil; 2005 May; 146(18 Suppl 1):900-4. PubMed ID: 15921302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?
    Pulsipher MA
    Pediatr Blood Cancer; 2004 Oct; 43(5):523-33. PubMed ID: 15382266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
    Simon W; Segel GB; Lichtman MA
    Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [An advance in the treatment of CML].
    Ohnishi K
    Gan To Kagaku Ryoho; 2007 Dec; 34(13):2185-90. PubMed ID: 18079618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
    Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
    J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
    Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
    Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?
    Maziarz RT
    Curr Opin Hematol; 2008 Mar; 15(2):127-33. PubMed ID: 18300759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and emerging treatment options in chronic myeloid leukemia.
    Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
    Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.
    Giralt SA; Arora M; Goldman JM; Lee SJ; Maziarz RT; McCarthy PL; Sobocinski KA; Horowitz MM;
    Br J Haematol; 2007 Jun; 137(5):461-7. PubMed ID: 17459051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of allogeneic transplantation in chronic myeloid leukemia.
    Heim D; Gratwohl A
    Expert Rev Hematol; 2008 Oct; 1(1):41-50. PubMed ID: 21083006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical decisions for chronic myeloid leukemia in the imatinib era.
    Goldman JM; Marin D; Olavarria E; Apperley JF
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):98-103; discussion 104-13. PubMed ID: 12783383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplantation for chronic myelogenous leukemia: yes, no, maybe so. . . An Oregon perspective.
    Maziarz RT; Mauro MJ
    Bone Marrow Transplant; 2003 Sep; 32(5):459-69. PubMed ID: 12942091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-Line management of CML: a state of the art review.
    Hochhaus A
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S1-S10. PubMed ID: 18397676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating children with chronic myeloid leukemia in the imatinib era: a therapeutic dilemma?
    Thornley I; Perentesis JP; Davies SM; Smith FO; Champagne M; Lipton JM
    Med Pediatr Oncol; 2003 Aug; 41(2):115-7. PubMed ID: 12825214
    [No Abstract]   [Full Text] [Related]  

  • 17. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.
    Suttorp M
    Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S40-6. PubMed ID: 18978743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing therapy of chronic myeloid leukemia.
    Deininger MW
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):144-54. PubMed ID: 17379100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of interferon-alpha in the treatment of chronic myeloid leukemia.
    Kujawski LA; Talpaz M
    Cytokine Growth Factor Rev; 2007; 18(5-6):459-71. PubMed ID: 17703986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission.
    Woods-Swafford W; Vnencak-Jones CL; Loken MR; Manes B; Frangoul H
    Pediatr Blood Cancer; 2008 Mar; 50(3):639-41. PubMed ID: 16927371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.